[Translated article] Risk stratification tool for pharmaceutical care in patients with cardiovascular disease

Objective: To develop a risk stratification tool for pharmaceutical care in patients with cardiovascular disease who require a comprehensive and personalized pharmaceutical approach. Method: The risk stratification model was collaboratively developed by hospital pharmacists specialized in managing c...

Descripción completa

Detalles Bibliográficos
Autores: Lopez, AD, Escrig, EV, Serrano, PS, Morillo-Verdugo, R
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2026
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:dnet:r-fisabio___::b50e0877e390245ac0304f16d90c8857
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/20606
Access Level:acceso abierto
Palabra clave:Pharmaceutical care
Hospital pharmacy
Outpatient
Cardiovascular risk
id ES_cfa1d9f3eecd48f8a2ca2c759632349f
oai_identifier_str oai:dnet:r-fisabio___::b50e0877e390245ac0304f16d90c8857
network_acronym_str ES
network_name_str España
repository_id_str
spelling [Translated article] Risk stratification tool for pharmaceutical care in patients with cardiovascular diseaseLopez, ADEscrig, EVSerrano, PSMorillo-Verdugo, RPharmaceutical careHospital pharmacyOutpatientCardiovascular riskObjective: To develop a risk stratification tool for pharmaceutical care in patients with cardiovascular disease who require a comprehensive and personalized pharmaceutical approach. Method: The risk stratification model was collaboratively developed by hospital pharmacists specialized in managing cardiovascular risk patients, all members of the Spanish Society of Hospital Pharmacy. Through three workshops and a pilot study, relevant variables were identified, grouped into four dimensions, and assigned relative weights. In the pilot study, data from patients in the participating centers were collected and analyzed to determine priority levels and assess the contribution of each variable. The Kaiser Permanente pyramidal model was adopted, classifying patients into three priority levels: priority 1 (intensive pharmaceutical care, 90th percentile), priority 2 (60-90th percentiles), and priority 3 (below the 60th percentile). Cut-off points were established based on this stratification, and each center recorded variables in an Excel sheet to calculate mean weighted scores per priority level and total risk scores. Results: Participants completed a questionnaire consisting of 20 variables grouped into four dimensions: demographic, socio-health and functional status, clinical and healthcare utilization, and treatment-related factors. Based on the tool application in a pretest study, the following cut-off points were established: 23 or more points for priority 1, 17-22 points for priority 2, and fewer than 16 points for priority 3. Over 80% of the total score was attributed to the dimensions of "clinical and healthcare utilization" and "treatment-related factors". Consequently, interventions based on the pharmaceutical care model were recommended for cardiovascular risk patients, tailored to their prioritization level. Conclusion: This stratification tool enables the identification of cardiovascular patients who require a higher level of pharmaceutical care, facilitating the adjustment of healthcare capacity. Validation of the model in a representative population is necessary to establish its broader applicability. (c) 2025 The Author(s). Published by Elsevier Espa & ntilde;a, S.L.U. on behalf of Sociedad Espa & ntilde;ola de Farmacia Hospitalaria (S.E.F.H). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ELSEVIER SCIENCE INC2026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/20606FARMACIA HOSPITALARIAISSN: 11306343ISSNe: 21718695reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:dnet:r-fisabio___::b50e0877e390245ac0304f16d90c88572026-06-11T12:45:17Z
dc.title.none.fl_str_mv [Translated article] Risk stratification tool for pharmaceutical care in patients with cardiovascular disease
title [Translated article] Risk stratification tool for pharmaceutical care in patients with cardiovascular disease
spellingShingle [Translated article] Risk stratification tool for pharmaceutical care in patients with cardiovascular disease
Lopez, AD
Pharmaceutical care
Hospital pharmacy
Outpatient
Cardiovascular risk
title_short [Translated article] Risk stratification tool for pharmaceutical care in patients with cardiovascular disease
title_full [Translated article] Risk stratification tool for pharmaceutical care in patients with cardiovascular disease
title_fullStr [Translated article] Risk stratification tool for pharmaceutical care in patients with cardiovascular disease
title_full_unstemmed [Translated article] Risk stratification tool for pharmaceutical care in patients with cardiovascular disease
title_sort [Translated article] Risk stratification tool for pharmaceutical care in patients with cardiovascular disease
dc.creator.none.fl_str_mv Lopez, AD
Escrig, EV
Serrano, PS
Morillo-Verdugo, R
author Lopez, AD
author_facet Lopez, AD
Escrig, EV
Serrano, PS
Morillo-Verdugo, R
author_role author
author2 Escrig, EV
Serrano, PS
Morillo-Verdugo, R
author2_role author
author
author
dc.subject.none.fl_str_mv Pharmaceutical care
Hospital pharmacy
Outpatient
Cardiovascular risk
topic Pharmaceutical care
Hospital pharmacy
Outpatient
Cardiovascular risk
description Objective: To develop a risk stratification tool for pharmaceutical care in patients with cardiovascular disease who require a comprehensive and personalized pharmaceutical approach. Method: The risk stratification model was collaboratively developed by hospital pharmacists specialized in managing cardiovascular risk patients, all members of the Spanish Society of Hospital Pharmacy. Through three workshops and a pilot study, relevant variables were identified, grouped into four dimensions, and assigned relative weights. In the pilot study, data from patients in the participating centers were collected and analyzed to determine priority levels and assess the contribution of each variable. The Kaiser Permanente pyramidal model was adopted, classifying patients into three priority levels: priority 1 (intensive pharmaceutical care, 90th percentile), priority 2 (60-90th percentiles), and priority 3 (below the 60th percentile). Cut-off points were established based on this stratification, and each center recorded variables in an Excel sheet to calculate mean weighted scores per priority level and total risk scores. Results: Participants completed a questionnaire consisting of 20 variables grouped into four dimensions: demographic, socio-health and functional status, clinical and healthcare utilization, and treatment-related factors. Based on the tool application in a pretest study, the following cut-off points were established: 23 or more points for priority 1, 17-22 points for priority 2, and fewer than 16 points for priority 3. Over 80% of the total score was attributed to the dimensions of "clinical and healthcare utilization" and "treatment-related factors". Consequently, interventions based on the pharmaceutical care model were recommended for cardiovascular risk patients, tailored to their prioritization level. Conclusion: This stratification tool enables the identification of cardiovascular patients who require a higher level of pharmaceutical care, facilitating the adjustment of healthcare capacity. Validation of the model in a representative population is necessary to establish its broader applicability. (c) 2025 The Author(s). Published by Elsevier Espa & ntilde;a, S.L.U. on behalf of Sociedad Espa & ntilde;ola de Farmacia Hospitalaria (S.E.F.H). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
publishDate 2026
dc.date.none.fl_str_mv 2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/20606
url https://fisabio.portalinvestigacion.com/publicaciones/20606
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER SCIENCE INC
publisher.none.fl_str_mv ELSEVIER SCIENCE INC
dc.source.none.fl_str_mv FARMACIA HOSPITALARIA
ISSN: 11306343
ISSNe: 21718695
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420100591812608
score 15,812429

Similares en LA Referencia